1.5800
-0.1000
(-5.95%)
At close: January 10 at 4:00:00 PM EST
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
2,308.0000
2,308.0000
--
--
15,183.0000
Operating Expense
30,943.0000
30,943.0000
24,147.0000
25,399.0000
21,559.0000
Operating Income
-28,635.0000
-28,635.0000
-24,147.0000
-25,399.0000
-6,376.0000
Net Non Operating Interest Income Expense
12.0000
12.0000
22.0000
2.0000
42.0000
Other Income Expense
1,574.0000
1,574.0000
3,389.0000
15.0000
-2,570.0000
Pretax Income
-27,049.0000
-27,049.0000
-20,736.0000
-25,382.0000
-8,904.0000
Tax Provision
-271.0000
-271.0000
-271.0000
-368.0000
-484.0000
Net Income Common Stockholders
-26,778.0000
-26,778.0000
-20,465.0000
-25,014.0000
-8,420.0000
Diluted NI Available to Com Stockholders
-26,778.0000
-26,778.0000
-20,465.0000
-25,014.0000
-8,420.0000
Basic EPS
-10.16
--
-11.25
-18.88
-7.16
Diluted EPS
-10.16
--
-11.25
-18.88
-7.16
Basic Average Shares
2,636.7630
--
1,842.8440
1,324.6770
1,176.7450
Diluted Average Shares
2,636.7630
--
1,842.8440
1,324.6770
1,176.7450
Total Expenses
30,943.0000
30,943.0000
24,147.0000
25,399.0000
21,559.0000
Net Income from Continuing & Discontinued Operation
-26,778.0000
-26,778.0000
-20,465.0000
-25,014.0000
-8,420.0000
Normalized Income
-26,895.8078
-26,895.8078
-23,808.7220
-25,028.7825
-5,989.6990
Interest Income
12.0000
12.0000
22.0000
2.0000
42.0000
Net Interest Income
12.0000
12.0000
22.0000
2.0000
42.0000
EBIT
-28,635.0000
-28,635.0000
-24,147.0000
-25,399.0000
-6,376.0000
EBITDA
-26,766.0000
-26,766.0000
-22,278.0000
-23,530.0000
-5,111.0000
Reconciled Depreciation
1,869.0000
1,869.0000
1,869.0000
1,869.0000
1,265.0000
Net Income from Continuing Operation Net Minority Interest
-26,778.0000
-26,778.0000
-20,465.0000
-25,014.0000
-8,420.0000
Total Unusual Items Excluding Goodwill
119.0000
119.0000
3,388.0000
15.0000
-2,570.0000
Total Unusual Items
119.0000
119.0000
3,388.0000
15.0000
-2,570.0000
Normalized EBITDA
-26,885.0000
-26,885.0000
-25,666.0000
-23,545.0000
-2,541.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0001
Tax Effect of Unusual Items
1.1922
1.1922
44.2780
0.2175
-139.6990
6/30/2021 - 1/6/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PHIO Phio Pharmaceuticals Corp.
1.6900
0.00%
SNGX Soligenix, Inc.
3.2000
-2.14%
ACXP Acurx Pharmaceuticals, Inc.
0.8082
+7.62%
CMRX Chimerix, Inc.
3.2500
-6.88%
GTBP GT Biopharma, Inc.
2.6500
+3.92%
ENVB Enveric Biosciences, Inc.
0.4020
-3.34%
ENTX Entera Bio Ltd.
2.4500
0.00%
COEP Coeptis Therapeutics Holdings, Inc.
7.57
+8.30%
TCBP TC Biopharm (Holdings) Plc
0.4005
-1.11%
BDRX Biodexa Pharmaceuticals Plc
4.5200
+3.91%